Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2008;117:2785-2792
Published online before print May 19, 2008, doi: 10.1161/CIRCULATIONAHA.107.741314
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
117/21/2785    most recent
CIRCULATIONAHA.107.741314v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mauldin, J. P.
Right arrow Articles by Hedrick, C. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mauldin, J. P.
Right arrow Articles by Hedrick, C. C.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*UniGene
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes
Related Collections
Right arrow Pathophysiology
Right arrow Type 2 diabetes
Right arrow Lipid and lipoprotein metabolism
Right arrowRelated Article

(Circulation. 2008;117:2785-2792.)
© 2008 American Heart Association, Inc.


Vascular Medicine

Reduced Expression of ATP-Binding Cassette Transporter G1 Increases Cholesterol Accumulation in Macrophages of Patients With Type 2 Diabetes Mellitus

Jeremy P. Mauldin, PhD; Melissa H. Nagelin, MS; Allison J. Wojcik, MS; Suseela Srinivasan, PhD; Marcus D. Skaflen, BS; Carlos R. Ayers, MD; Coleen A. McNamara, MD; Catherine C. Hedrick, PhD

From the Cardiovascular Research Center (J.P.M., M.H.N., A.J.W., S.S., M.D.S., C.A.M., C.C.H.), Department of Pharmacology (J.P.M., M.H.N., A.J.W., C.C.H.), and Department of Internal Medicine (C.R.A., C.A.M., C.C.H.), University of Virginia, Charlottesville.

Correspondence to Catherine C. Hedrick, PhD, Cardiovascular Research Center, University of Virginia, 415 Lane Rd, Bldg MR-5, Room G123, PO Box 801394, Charlottesville, VA 22908. E-mail cch6n{at}virginia.edu

Received September 20, 2007; accepted April 2, 2008.

Background— Patients with type 2 diabetes mellitus are at increased risk for the development of atherosclerosis. A pivotal event in the development of atherosclerosis is macrophage foam cell formation. The ATP-binding cassette (ABC) transporters ABCA1 and ABCG1 regulate macrophage cholesterol efflux and hence play a vital role in macrophage foam cell formation. We have previously found that chronic elevated glucose reduces ABCG1 expression. In the present study, we examined whether patients with type 2 diabetes mellitus had decreased ABCG1 and/or ABCA1, impaired cholesterol efflux, and increased macrophage foam cell formation.

Methods and Results— Blood was collected from patients with and without type 2 diabetes mellitus. Peripheral blood monocytes were differentiated into macrophages, and cholesterol efflux assays, immunoblots, histological analysis, and intracellular cholesteryl ester measurements were performed. Macrophages from patients with type 2 diabetes mellitus had a 30% reduction in cholesterol efflux with a corresponding 60% increase in cholesterol accumulation relative to control subjects. ABCG1 was present in macrophages from control subjects but was undetectable in macrophages from patients with type 2 diabetes mellitus. In contrast, ABCA1 expression in macrophages was similar in both control subjects and patients with type 2 diabetes mellitus. Macrophage expression of ABCG1 in both patients and control subjects was induced by treatment with the liver X receptor agonist TO-901317. Upregulation of liver X receptor dramatically reduced foam cell formation in macrophages from patients with type 2 diabetes mellitus.

Conclusions— ABCG1 expression and cholesterol efflux are reduced in patients with type 2 diabetes mellitus. This impaired ABCG1-mediated cholesterol efflux significantly correlates with increased intracellular cholesterol accumulation. Strategies to upregulate ABCG1 expression and function in type 2 diabetes mellitus could have therapeutic potential for limiting the accelerated vascular disease observed in patients with type 2 diabetes mellitus.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2008 117: 2719-2720. [Extract] [Full Text]



This article has been cited by other articles:


Home page
J. Lipid Res.Home page
A. Baldan, D. D. Bojanic, and P. A. Edwards
The ABCs of sterol transport
J. Lipid Res., April 1, 2009; 50(Supplement): S80 - S85.
[Abstract] [Full Text] [PDF]